Navigation Links
CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
Date:3/3/2008

VIENNA, Va., March 3 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) provided details today at its 2008 Annual Meeting of Shareholders on groundbreaking activities currently underway at its manufacturing facility near Baltimore, Maryland. The facility will be used to manufacture Multikine(R), the Company's lead compound, for a pivotal Phase III clinical trial as first-line therapy of previously untreated head and neck cancer patients. The facility, which is being built by the design builder BE&K (http://www.bek.com/index.asp), is expected to be completed during the third quarter of 2008, with manufacturing and patient enrollment to begin soon thereafter.

"I am excited to announce to our shareholders the excellent progress we have made in constructing our manufacturing facility in the short period of time since we have broken ground," said Geert Kersten, CEL-SCI's Chief Executive Officer. "We believe the facility will provide us with tight control over the manufacturing process, eliminating a key risk of the pivotal trial. Multikine represents a completely novel medicine with blockbuster potential to treat a large unmet medical need and we are eager to begin this open label trial."

Mr. Kersten continued, "We are starting to receive more recognition for our work. The February 2008 issue of MedAdNews, a highly respected and authoritative publication serving the pharmaceutical industry, ran its 8th annual report on FUTURE BLOCKBUSTERS stating that 'These medicines are expected to eventually garner FDA approval and break the annual billion-dollar sales barrier'. Our Multikine was one of the 10 medicines named."

The article can be accessed on CEL-SCI's website at http://www.cel-sci.com under recent media coverage.

At the Annual Shareholder's Meeting, the Company's executives also provided highlights from fiscal year 2007. Some of the highlights include:

-- FDA clearance of Multikine for Phase III clinical trial in head and

neck cancer

-- Raised U.S. $15 million

-- Multikine granted Orphan drug designation in U.S.

-- Started build-out of manufacturing facility for Multikine to support

upcoming Phase III study and future commercial sale

-- Started planning and pricing of global clinical trial designed to lead

to marketing approval for Multikine

All matters submitted to a vote of the shareholders were approved by a vote of the shareholders at the Annual Meeting.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2007. The Company undertakes no obligation to publicly release the result of any revision to these forward- looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
3. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
4. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
5. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
6. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
7. Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date
8. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
9. National Atlantic Holdings Corporation to Report Fourth Quarter and Year-End 2007 Earnings on March 17, 2008
10. Linkwell Corporations Skin Disinfectant Product Chosen for 2008 Beijing Olympic Games
11. Partners Center for Connected Health and EMC Corporation Launch New Web-Based Remote Monitoring Program to Help Employees Fight Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... flexibility in repaying their loans, more information about their loan terms and accounts, ... outstanding student loan debt, including federal and private loans, has reached $1.3 trillion, ...
(Date:4/29/2016)... ... 29, 2016 , ... The Wharton School of the ... Prize of the 2016 Wharton Business Plan Competition —as well as the ... and the Committee Award for Most ‘Wow Factor,’ making them the first team ...
(Date:4/29/2016)... ... , ... Dr. Robert Mondavi, one of the dentists in Torrance , ... fast-growing field as more patients are discovering the many different ways they can change ... currently available to them and which ones might work for their smiles. , ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... Grassland Dairy Products, Inc. in an upcoming episode, airing third quarter 2016 via ... of churning cream into butter, Grassland Dairy Products, located in Greenwood, Wisconsin applies ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... Expo to promote their animal line of probiotics, Petbiotics ™, as they ... large turnout of animal rescue groups networking for their non-profit organizations. Animal rescues ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed ... a clinical-stage pharmaceutical company focused on the development of oral ... in the upcoming PIONEERS 2016 conference, presented by Joseph ... 2016 in New York . Nadav ... at the conference. Presentation Details:   ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... New York , April 27, 2016 ... market report titled, "Skincare Devices Market - Global Industry ... 2023." According to the report, the global skincare devices ... and is anticipated to expand at a CAGR of ... Mn in 2023. Browse the full Skincare Devices ...
Breaking Medicine Technology: